rss
J Neurol Neurosurg Psychiatry 74:863-866 doi:10.1136/jnnp.74.7.863
  • Paper

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial

  1. S Akhondzadeh1,*,
  2. M Noroozian1,
  3. M Mohammadi1,
  4. S Ohadinia2,
  5. A H Jamshidi2,
  6. M Khani2
  1. 1Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2Institute of Medicinal Plants, Iranian Academic Centre for Education, Culture and Research, Tehran
  1. Correspondence:
 Dr Shahin Akhondzadeh, Associate Professor, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Avenue, Tehran 13334, Iran;
 s.akhond{at}neda.net
  • Received 8 November 2002
  • Accepted 9 March 2003
  • Revised 18 January 2003

Abstract

Objective: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer’s disease.

Design: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran.

Methods: Patients with mild to moderate Alzheimer’s disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of ≥ 12 on the cognitive subscale of Alzheimer’s disease assessment scale (ADAS-cog) and ≤ 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded.

Results: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03).

Conclusions:Melissa officinalis extract is of value in the management of mild to moderate Alzheimer’s disease and has a positive effect on agitation in such patients.

Footnotes

  • Competing interests: none declared

  • * The roles in the study of the coauthors are given in the appendix

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article